Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic conditions, announced its participation in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
Two key presentations are scheduled: CFO Sylvia Cheung will deliver a corporate update available via webcast at 7:00am ET, while R&D President Snehal Shah will participate in a panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00am to 12:00pm ET. Both presentations will be accessible for replay through Oculis' website.
Oculis Holding AG (Nasdaq: OCS), società biofarmaceutica globale specializzata in patologie oftalmiche e neuro-oftalmiche, ha annunciato la partecipazione al H.C Wainwright 5th Annual Ophthalmology Virtual Conference il 13 agosto 2025.
Sono previste due presentazioni principali: CFO Sylvia Cheung terrà un aggiornamento aziendale trasmesso via webcast alle 7:00 ET, mentre R&D President Snehal Shah parteciperà a una tavola rotonda sugli asset in fase pivotale per i disturbi retinici dalle 11:00 alle 12:00 ET. Entrambe le presentazioni saranno disponibili in replica sul sito web di Oculis.
Oculis Holding AG (Nasdaq: OCS), compañía biofarmacéutica global especializada en afecciones oftálmicas y neurooftálmicas, anunció su participación en el H.C Wainwright 5th Annual Ophthalmology Virtual Conference el 13 de agosto de 2025.
Se han programado dos presentaciones principales: CFO Sylvia Cheung ofrecerá una actualización corporativa vía webcast a las 7:00 ET, mientras que R&D President Snehal Shah participará en una mesa redonda sobre activos en fase pivotal para trastornos retinianos de 11:00 a 12:00 ET. Ambas presentaciones estarán disponibles en reproducción en el sitio web de Oculis.
Oculis Holding AG (Nasdaq: OCS), 안과 및 신경안과 질환을 전문으로 하는 글로벌 바이오제약 회사가 H.C Wainwright 5th Annual Ophthalmology Virtual Conference에 2025년 8월 13일 참가한다고 발표했습니다.
두 가지 주요 발표가 예정되어 있습니다: CFO Sylvia Cheung는 ET 기준 오전 7시에 웹캐스트로 기업 업데이트를 진행하고, R&D President Snehal Shah는 ET 기준 오전 11시부터 정오까지 망막 질환 관련 피보탈 단계(중요 단계) 자산을 주제로 한 패널 토론에 참여합니다. 두 발표 모두 Oculis 웹사이트에서 다시보기로 시청할 수 있습니다.
Oculis Holding AG (Nasdaq: OCS), société biopharmaceutique mondiale spécialisée dans les affections ophtalmiques et neuro-ophtalmiques, a annoncé sa participation au H.C Wainwright 5th Annual Ophthalmology Virtual Conference le 13 août 2025.
Deux présentations principales sont prévues : CFO Sylvia Cheung présentera une mise à jour d'entreprise diffusée en webcast à 7h00 ET, tandis que R&D President Snehal Shah participera à un panel sur les actifs en phase pivotale pour les affections rétiniennes de 11h00 à 12h00 ET. Les deux présentations seront accessibles en replay sur le site d'Oculis.
Oculis Holding AG (Nasdaq: OCS), ein globales biopharmazeutisches Unternehmen, das sich auf ophthalmologische und neuro-ophthalmologische Erkrankungen spezialisiert hat, gab seine Teilnahme am H.C Wainwright 5th Annual Ophthalmology Virtual Conference am 13. August 2025 bekannt.
Es sind zwei Hauptpräsentationen vorgesehen: CFO Sylvia Cheung wird um 7:00 Uhr ET ein Unternehmens-Update per Webcast vorstellen, während R&D President Snehal Shah von 11:00 bis 12:00 Uhr ET an einer Podiumsdiskussion über Assets in pivotaler Phase für Netzhauterkrankungen teilnimmt. Beide Präsentationen werden zur Wiedergabe auf der Website von Oculis verfügbar sein.
- None.
- None.
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis’ management will be participating in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.
- Sylvia Cheung, Oculis’ Chief Financial Officer, will be presenting a corporate update which will be made available for replay via webcast at 7:00am ET
- Snehal Shah, Oculis’ President of R&D, will be participating in a live panel discussion from 11:00am to 12:00pm ET, on Pivotal-Stage Assets for Retinal Disorders. The panel discussion will also be made available via webcast for replay.
Links to access the corporate update presentation and the panel discussion will be posted to Oculis’ website on the Events & Presentation page under the Investors & Media section.
- ENDS -
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
FAQ
When is Oculis (OCS) presenting at the H.C Wainwright Ophthalmology Conference 2025?
Who are the Oculis executives presenting at the H.C Wainwright Conference?
How can investors access Oculis' (OCS) H.C Wainwright Conference presentations?
What topics will be covered in Oculis' panel discussion at the H.C Wainwright Conference?
